# UpFrontPSMA (NCT04343885)

> In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

No report yet. It can be ordered.

- Drugs tested: 177Lu-PSMA-617
- Indication: metastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04343885
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Metastatic Hormone Naive Prostate Cancer
- Interventions: 177Lu-PSMA-617; Docetaxel
- Enrollment: 130
- Primary outcome: Undetectable prostate specific antigen (PSA) rate at 12 months after commencement of protocol therapy

## Indexed commentary on UpFrontPSMA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=upfrontpsma-nct04343885